HighCom Ltd

Brenus Pharma Initiates First-in-Human Trial of STC-1010 Immunotherapy for Advanced Colorectal Cancer

- Brenus Pharma has successfully dosed the first patients in a Phase I/IIa trial evaluating STC-1010, a novel in vivo immunotherapy for unresectable, locally advanced or metastatic colorectal cancer. - The first patient completed eight weeks of treatment with no adverse events attributed to the investigational therapy, with three patients already enrolled in the study. - The international "BreAK CRC-001" trial will assess STC-1010 in combination with immunostimulatory agents and standard chemotherapy in over 80 patients, with first results expected in the first half of 2026. - The therapy targets pMMR/MSS colorectal cancer patients who have limited immunotherapy options, aiming to convert "cold" tumors into "hot" tumors responsive to immune attack.